GSK

GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication

Leave a Comment / Blogger, Uncategorized / By

Dear HIV Community Writer, ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine.  This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that …

GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication Read More »

GSK is Exploring a Once a Month Injectable HIV Treatment Regimen

Leave a Comment / Blogger, Uncategorized / By

Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults          Presented at the International AIDS Conference in Washington this week Discussion  — S/GSK1265744 long acting parenteral administration prolonged plasma levels (apparent t1/2of 2150days; Figure 4) compared with oral administration (oral …

GSK is Exploring a Once a Month Injectable HIV Treatment Regimen Read More »

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

Leave a Comment / Blogger, Uncategorized / By

This drug will compete against raltegravir (Merck) and elvitegravir (Gilead).  It will be dosed once a day for treatment naive patients and twice a day for treatment experienced. Issued: Monday 02 April 2012, London, UK Press release issued by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established …

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

Leave a Comment / Blogger, Uncategorized / By

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients

Leave a Comment / Blogger, Uncategorized / By

https://clinicaltrials.gov/ct2/show/NCT01328041?term=dolutegravir&rank=1 For more on dolutegravir: Report from CROI 2011 Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort …

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients Read More »

Dolutegravir, Trii and new abacavir data- How it all ties together

Leave a Comment / Blogger, Uncategorized / By

By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took …

Dolutegravir, Trii and new abacavir data- How it all ties together Read More »

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options

Leave a Comment / Blogger, Uncategorized / By

Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »